PORRE GRANDE ATTENZIONE! Uno studio scientifico pone in evidenza il rischio di cosiddetti “vaccini” per il SARS CORONAVIRUS (e quindi covid-19).
Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with SARS ViruS
COVID-19 Vaccines: Should We Fear ADE?
Scott B Halstead, Leah Katzelnick
Might COVID-19 vaccines sensitize humans to antibody-dependent enhanced (ADE) breakthrough infections? This is unlikely because coronavirus diseases in humans lack the clinical, epidemiological, biological, or pathological attributes of ADE disease exemplified by dengue viruses (DENV). In contrast to DENV, SARS and MERS CoVs predominantly infect respiratory epithelium, not macrophages. Severe disease centers on older persons with preexisting conditions and not infants or individuals with previous coronavirus infections. Live virus challenge of animals given SARS or MERS vaccines resulted in vaccine hypersensitivity reactions (VAH), similar to those in humans given inactivated measles or respiratory syncytial virus vaccines. Safe and effective COVID-19 vaccines must avoid VAH.
Keywords: SARS-CoV-2; T cells; antibody-dependent enhancement (ADE); coronavirus; dengue; dengue hemorrhagic fever; hypersensitivity; immunopathology; vaccine; vaccine adverse events.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: email@example.com. Review Paediatr Respir Rev . 2020 Sep;35:43-49. doi: 10.1016/j.prrv.2020.06.010. Epub 2020 Jun 18.
ALTRI ARTICOLI RECENTI:
Vaccines for COVID-19: The current state of play
Free PMC article
There is a strong consensus globally that a COVID-19 vaccine is likely the most effective approach to sustainably controlling the COVID-19 pandemic. An unprecedented research effort and global coordination has resulted in a rapid development of vaccine candidates and initiation of trials. Here, we review vaccine types, and progress with 10 vaccine candidates against SARS-CoV-2 – the virus that causes COVID-19 – currently undergoing early phase human trials. We also consider the many challenges of developing and deploying a new vaccine on a global scale, and recommend caution with respect to our expectations of the timeline that may be ahead.
Keywords: Covid 19; Human trials; Timeline; Vaccines.
Copyright © 2020 Elsevier Ltd. All rights reserved. Review Int J Biol Macromol. 2020 Dec 1;164:331-343. doi: 10.1016/j.ijbiomac.2020.07.106. Epub 2020 Jul 14.
Application prospect of polysaccharides in the development of anti-novel coronavirus drugs and vaccines
Free PMC article
Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, it has spread rapidly worldwide and poses a great threat to public health. This is the third serious coronavirus outbreak in <20 years, following SARS in 2002-2003 and MERS in 2012. So far, there are almost no specific clinically effective drugs and vaccines available for COVID-19. Polysaccharides with good safety, immune regulation and antiviral activity have broad application prospects in anti-virus, especially in anti-coronavirus applications. Here, we reviewed the antiviral mechanisms of some polysaccharides, such as glycosaminoglycans, marine polysaccharides, traditional Chinese medicine polysaccharides, and their application progress in anti-coronavirus. In particular, the application prospects of polysaccharide-based vaccine adjuvants, nanomaterials and drug delivery systems in the fight against novel coronavirus were also analyzed and summarized. Additionally, we speculate the possible mechanisms of polysaccharides anti-SARS-CoV-2, and propose the strategy of loading S or N protein from coronavirus onto polysaccharide capped gold nanoparticles vaccine for COVID-19 treatment. This review may provide a new approach for the development of COVID-19 therapeutic agents and vaccines.
Keywords: Antiviral activity; COVID-19; Coronavirus; Mechanism; Polysaccharides; SARS-CoV-2.
Copyright © 2020 Elsevier B.V. All rights reserved.